JC07 Rec'd POT/9TO 1 3 NOV 200

BOX SEQUENCE

IN THE U.S. PATERIT AND TRADEMARK OFFICE

Applicant:

L. STEINAA et al.

Conf.:

5928

Appl. No.:

09/305,703

Group:

UNEMOWN

Filed:

April 4, 2001

Examiner: UNFNOWN



NOVEL METHODS FOR THERAPEUTIC VACCINATION

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents Washington, DC 20231

November 13, 2001 (Tuesday after Holiday)

Sir:

Transmitted herewith is an amendment in the above-identified application.

The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENOMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		SRESENT EXTRA	BATE	ACCITI MAL FEE
TOTAL	92	-	92	=	()	\$ 13	\$0.00
INCEPENDENT	2	-	3	=	()	\$ 80	\$0.00
FIRST PRESENTATION OF A MULTIPLE CLAIM					\$270	\$0.00	
						TOTAL	\$0.00

Docket No. 3631-0109P

		month s extension of time pursuant 1.136 a. 30.00 for the extension of			
×	No fee is required.				
	A sheck in the amount of \$1.00 is enclosed.				
	Please charge Deposit Account No. 02-2448 in the amount of $\$0.00$. This form is submitted in triplicate.				
	If necessary, the Commis	ssibner is hereby authorized in this,			
concurrent, and future replies, to charge payment or credit any					
overpayment to Deposit Account No. 02-2448 for any additional fees					
required under 37 C.F.R. §§1.16 or 1.17; particularly, extension					
of time fees.					
		Respectfully submitted,			
		BIFCH, STEWART, KOLASCH & BIRCH, LLP			
		By			
		Falls Church, VA 22040-0747 (703) 205-8000			

Attachment



BOX SEQUENCE PATHNTL
3631-0109PL
1000

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

L. STEINAA et al.

Conf.:

5928

Appl. No.:

09/806,703

Group:

OHENGMI

Filed:

April 4, 2001

Examiner: UNKNOWN

For:

NOVEL METHODS FOR THERAPEUTIC VACCINATION

AMENDMENT

Assistant Commissioner for Patents Washington, DC 20231

November 13, 2001 (Tuesday after Holiday)

Sir:

In response to the Notification of Defective Response mailed October 11, 2001, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

In the Specification:

Please replace the paragraph beginning on page 14, line 12, with the following rewritten paragraph:

--Fig. 5: The FGF genes and proteins. A: Exon-intron structure of the human and mouse FGF8 genes. Below is illustrated the eight different splice forms (from Gemel 1996). B: Amino acid sequence (SEQ ID NO: 34) of the different FGF6 isoforms. The polypeptide stretches unique to FGF8b, FGF8f, and FGF8e are